Neurocrine Biosciences, Inc.

NASDAQ:NBIX   3:59:40 PM EDT
92.04
-0.11 (-0.12%)
Products, Regulatory

Voyager Therapeutics Provides Update On Nbib-1817 (Vy-Aadc) Gene Therapy Program

Published: 12/22/2020 22:00 GMT
Neurocrine Biosciences, Inc. (NBIX) - Voyager Therapeutics Provides Update on Nbib-1817 (vy-aadc) Gene Therapy Program.
Voyager Therapeutics Inc - FDA Notified Neurocrine Biosciences That It Has Placed a Clinical Hold on Restore-1 Clinical Trial of Nbib-1817.
Voyager Therapeutics Inc - Neurocrine Biosciences and Co Will Work Closely With FDA and Dsmb to Determine Next Steps for Restore-1 Clinical Trial.
Voyager Therapeutics - Dsmb Has Requested Additional Patient Level Data From Restore-1 Clinical Trial, Now Plans to Review These Data in Early 2021.